Based in Cambridge, UK, Bicycle Therapeutics, the latest LMB spin out, will combine the most desirable features of small molecules and biologics to create highly specific and stable drugs. Bicycle Therapeutics has developed a new novel technology platform using phage display to select peptidic sequences that are cyclized on a chemical core. Sir Gregory Winter […]
LMB News
Jason Chin to present the annual Francis Crick Lecture for the Royal Society.
Dr Jason Chin, from the Division of Protein and Nucleic Acid Chemistry (PNAC) at LMB, has been chosen to present the annual Francis Crick Lecture for the Royal Society on 26 November 2009. In his Francis Crick prize lecture entitled “Reprogramming the code of life”, Dr Jason Chin will discuss the invention and synthetic evolution […]
EMBO Young Investigator Award for Madan Babu.
Dr Madan Babu has been selected as an EMBO Young Investigator. The European Molecular Biology Organization (EMBO) set up their Young Investigator programme ten years ago which identifies some of Europe’s most promising and creative young life scientists. This year, the programme received 123 applications out of which 17 were selected. The 2009 EMBO Young […]
Heptares Therapeutics Announces Agreement With Novartis Option Fund
Heptares Therapeutics Ltd, the drug discovery company focused on G-protein-coupled receptor (GPCR) targets, has recently announced that it has entered into an option agreement with the Novartis Option Fund under which Heptares will apply its proprietary StaR(TM) technology to generate novel drug leads against a nominated, unspecified GPCR target of interest to Novartis. The agreement […]
Dr Venki Ramakrishnan wins 2009 Nobel Prize for Chemistry
This year’s chemistry Nobel Prize has been awarded to Dr Venki Ramakrishnan of LMB for “studies of the structure and function of the ribosome”. Venki Ramakrishnan shares the honour with Thomas A. Steitz (Yale University) and Ada E. Yonath (Weizmann Institute of Science, Israel). The trio showed how the information encoded on strands of DNA […]
Human Antibodies developed for Treatment of Lupus and Anthrax
Two therapies with their roots in antibody technology developed in the LMB and the Scripps Research Institute* have recently emerged as promising new drug candidates to treat lupus, a potentially fatal autoimmune disease, and anthrax, a pressing concern due to bioterrorism. The drug candidates—belimumab (BENLYSTATM, formerly LumphoStat-B®), developed by Human Genome Sciences with GlaxoSmithKine as […]